Kerlann Pte Ltd
Biotech Partnering Across Borders
Kerlann supports selected biotech teams, asset owners, and global pharma groups with partner identification, asset positioning, cross-border licensing, and deal execution support.
Get in touch
Partnering Discussions
For biotech partnering, licensing, or asset strategy discussions, contact Kerlann. Initial conversations are handled by a founding partner.
About
Kerlann is a boutique life sciences advisory. We work with a small number of biotech companies, asset owners, and investors on partnering, licensing, and cross-border business development.
Engagements are principal-led and discreet, with active networks across the United States, Europe, Japan, and China.
What we do
Supporting Both Sides of Partnering
Kerlann works across the biotech partnering market, with clear engagement boundaries. We help biotech companies and asset owners prepare assets for partner discussions, identify relevant counterparties, and support licensing or co-development processes. We also help global pharma and established biopharma teams map external innovation, screen differentiated assets, and assess strategic fit across priority therapeutic areas and geographies.
This dual perspective helps us understand how opportunities are evaluated on both sides of the table.
For Biotechs and Asset Owners
- Asset positioning
- Partner prioritization
- Non-confidential materials
- Licensing and co-development support
- Diligence preparation
For Pharma and MNCs
- External innovation mapping
- Asset scouting
- Strategic fit assessment
- Cross-border opportunity screening
- Partnering thesis validation
How we engage
From First Fit to Executable Partnership
Kerlann's role does not stop at identifying counterparties. We help prepare the asset story, sharpen the strategic fit, anticipate diligence questions, coordinate technical follow-up, and support negotiation structure so that promising conversations can move toward executable partnerships.
01
Position the Asset
Clarify differentiation, evidence package, partner-specific rationale, and likely objections before outreach.
02
Prepare the Conversation
Develop non-confidential materials, outreach logic, and first-call framing for the right counterparties.
03
Support Diligence
Coordinate scientific, clinical, regulatory, CMC, and commercial follow-up so momentum is not lost after the first discussion.
04
Structure the Path Forward
Support term-sheet logic, collaboration models, negotiation preparation, and cross-border coordination.
Cross-border reach
China-Grounded, Globally Oriented
Kerlann works with senior collaborators on the ground in China to support asset sourcing, company dialogue, and cross-border partnering preparation. This local access helps bridge China-originated biotech innovation with global BD expectations across the US, Europe, Japan, and Singapore.
- China-originated asset positioning
- Local company dialogue
- Cross-border diligence preparation
- Global partner prioritization
- US, Europe, Japan, and Singapore BD alignment
How we work
Engagement Principles
Principal-led
Every engagement is led directly by a founding partner. No junior layers, no hand-offs.
Discreet process
We work quietly and selectively. Confidentiality is maintained throughout every discussion.
Clear scope
Mandates are defined upfront with explicit deliverables, timelines, and decision gates.
Where we focus
Areas of Focus
Kerlann focuses on biotech assets and platforms where cross-border partnering, external innovation fit, and deal structure matter early.
Oncology Biologics and Immunotherapy
ADCs, ISACs, T-cell engagers, innate checkpoint antibodies, oncolytic viruses, and therapeutic cancer vaccines.
Cell Therapy and TCR-Based Platforms
TCR-T, CAR-T, soluble TCR engagers, multi-epitope approaches, and solid-tumor cell therapy strategies.
Oligonucleotide and Antiviral Therapeutics
ASO, LNA/cLNA, siRNA, and HBV functional-cure combination strategies.
Targeted Radiopharmaceuticals
Radioligand and radionuclide drug conjugate platforms with human imaging, biodistribution, and theranostic potential.
Immunology, CNS, and Specialty Biologics
Differentiated antibodies, long-acting biologics, and immune-modulating assets in immunology, neurodegeneration, and specialty indications.
China-Originated Innovation and Cross-Border Partnering
China-based or China-originated biotech assets preparing for global partnering, licensing, or co-development discussions across the US, Europe, Japan, and Singapore.
Team
Partner-Led, Discreet by Design
Kerlann is led by a small founding team with complementary experience across life sciences strategy, business development, market access, and cross-border execution, including active China coverage through senior collaborators on the ground.
We keep the public profile intentionally discreet. Client engagements are partner-led, with selected senior specialists brought in when clinical, regulatory, market access, or regional expertise is required.
For partnering inquiries, please contact Kerlann. Initial conversations are handled directly by a founding partner.
Data-Driven Partnering Intelligence
We combine senior judgment with structured market mapping, competitive intelligence, and partner prioritization workflows.
Insights
Insights on Biotech Partnering
Selected notes on asset strategy, partnership structures, and cross-border biotech business development.
Series · 10-part
Cell Therapy Partnership Strategy
A 10-part series on how cell therapy assets are evaluated, structured, and partnered — written for biotech BD teams and external innovation leads weighing in-licensing, co-development, or acquisition.
- China-Originated Innovation25 August 2026
China-Originated Assets: A Western BD Reader's Guide to Diligence
The diligence questions that matter most for a China-originated asset aren't the usual ones. Export approvals, data comparability, and regulatory screening deserve earlier attention than valuation.
- China-Originated Innovation25 August 2026
Out-Licensing from China: Sequencing US, EU, and Japan Conversations
Parallel conversations with US, European, and Japanese partners aren't independent processes. Sequencing them well protects leverage; getting the order wrong gives it away.
- China-Originated Innovation10 August 2026
Shanghai's First Deal Room: What We Saw at CPIC 2026
Kerlann spent CPIC 2026 in Shanghai's exhibition halls and BD sessions. Here's what the conference's first edition tells us about where China pharma dealmaking is headed.
- Singapore-based
- Principal-led engagements
- Cross-border BD and licensing
- US · Europe · Japan · China networks